NanoAssemblr Blaze: Rapid scaling of nanoparticle formulations

In this video we demonstrate the NanoAssemblr Blaze, which allows rapid scaling of nanoparticle formulations for late pre-clinical development.
The system can manufacture between 10 mL and 10 L of formulation which allows researchers to use the Blaze for preclinical toxicology testing, and for early Chemistry, Manufacturing and Controls studies.
A candidate drug must be shown to be both potent and non-toxic in relevant models. While early screening in murine models is enough to begin a program, the demands for data from larger models will increase. Traditionally, process development for nanomedicine production at an intermediate scale is a barrier to this work.
With NxGen technology on the NanoAssemblr Blaze, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
Contact us today to request a quote or learn more at www.cytiva.com/